Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 4/20 | 0.37 |
| ▸ | CASP2 | P42575 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6701235 | 0.83 | — | — | |
| SCHEMBL17663629 | 0.82 | GAA (0.49) | GAAPAOXEPHX1MEN1KMT2A | |
| SCHEMBL20095068 | 0.82 | GAA (0.53) | GAAEPHX1HDAC1HDAC2TSHR | |
| SCHEMBL28528638 | 0.82 | GAA (0.56) | GAAPAOXEPHX1HDAC1HDAC2 | |
| Hydrochloric Acid SCHEMBL3946348 | 0.81 | GAA (0.50) | GAAPAOXEPHX1HDAC1HDAC2 | |
| SCHEMBL24393668 | 0.79 | MCL1 (0.35) | GAAMEN1KMT2ADPP4FAAH | |
| SCHEMBL21440848 | 0.79 | MCL1 (0.35) | GAAMEN1KMT2ADPP4FAAH | |
| SCHEMBL21440822 | 0.79 | MCL1 (0.35) | GAAMEN1KMT2ADPP4FAAH | |
| SCHEMBL25661969 | 0.79 | MCL1 (0.35) | GAAMEN1KMT2ADPP4FAAH | |
| SCHEMBL4985640 | 0.79 | FAAH (0.49) | GAAEPHX1TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174301-B2 | Peptide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-16 | — | — | US | disclosed |
| US-20200140505-A1 | PEPTIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140505-A1 | PEPTIDE COMPOUND | GIPR, GLP1R, GRPR | GAA 2595/4885PAOX 3571/4885EPHX1 4810/4885 |
| US-11174301-B2 | Peptide compound | GIPR, GLP1R, GRPR | GAA 2595/4885PAOX 3571/4885EPHX1 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.